Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 18/20 | 1.00 |
| ▸ | INSR | P06213 | 15/20 | 1.00 |
| ▸ | IGF1R | P08069 | 15/20 | 1.00 |
| ▸ | AURKA | O14965 | 2/20 | 1.00 |
| ▸ | ROS1 | P08922 | 2/20 | 1.00 |
| ▸ | EML4 | Q9HC35 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 4/20 | 0.77 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.77 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.77 |
| ▸ | JAK2 | O60674 | 1/20 | 0.77 |
| ▸ | STK10 | O94804 | 1/20 | 0.77 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.77 |
| ▸ | SLC34A2 | O95436 | 1/20 | 0.77 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.77 |
| ▸ | ABL1 | P00519 | 1/20 | 0.77 |
| ▸ | CD74 | P04233 | 1/20 | 0.77 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.77 |
| ▸ | LCK | P06239 | 1/20 | 0.77 |
| ▸ | FYN | P06241 | 1/20 | 0.77 |
| ▸ | FES | P07332 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29489146 | 1.00 | ALK (1.00) | ALKINSRIGF1RAURKAROS1 | |
| SCHEMBL11916451 | 0.95 | ALK (1.00) | ALKINSRIGF1RAURKAROS1 | |
| SCHEMBL15217780 | 0.95 | ALK (1.00) | ALKINSRIGF1RAURKAROS1 | |
| SCHEMBL21709647 | 0.93 | ALK (0.87) | ALKINSRIGF1RAURKAROS1 | |
| SCHEMBL17410898 | 0.93 | ALK (0.86) | ALKINSRIGF1RAURKAROS1 | |
| SCHEMBL11916574 | 0.91 | ALK (0.86) | ALKINSRIGF1RAURKAROS1 | |
| SCHEMBL21135587 | 0.91 | ALK (0.86) | ALKINSRIGF1RAURKAROS1 | |
| SCHEMBL21133486 | 0.90 | ALK (0.85) | ALKINSRIGF1RAURKAROS1 | |
| SCHEMBL11916602 | 0.90 | ALK (0.85) | ALKINSRIGF1RAURKAROS1 | |
| SCHEMBL11916477 | 0.90 | ALK (1.00) | ALKINSRIGF1RAURKAROS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 262 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4221706-B1 | TREATMENT FOR VIRAL INFECTION | UNIV OSLO HF (NO) | 2026-04-15 | — | — | EP | claimed |
| EP-3453392-B1 | THERAPEUTIC AGENT FOR LUNG CANCER THAT HAS ACQUIRED EGFR-TKI RESISTANCE | JAPANESE FOUND FOR CANCER RES (JP) | 2025-10-22 | — | — | EP | claimed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | claimed |
| WO-2024249331-A1 | COMBINED RTK AND ALK INHIBITION IN RTK DRIVEN CANCERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-12-05 | — | — | WO | claimed |
| WO-2024102187-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | PINETREE THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | WO | claimed |
| US-20240009213-A1 | TREATMENT FOR VIRAL INFECTION | OSLO UNIVERSITETSSYKEHUS HF (NO) | 2024-01-11 | — | — | US | claimed |
| US-11723891-B2 | Drug combinations for use in the treatment of RAS-mutant cancer | UMC UTRECHT HOLDING B.V. (NL) | 2023-08-15 | — | — | US | claimed |
| EP-4221706-A1 | TREATMENT FOR VIRAL INFECTION | Oslo Universitetssykehus HF (NO) | 2023-08-09 | — | — | EP | claimed |
| WO-2022069684-A1 | TREATMENT FOR VIRAL INFECTION | OSLO UNIVERSITETSSYKEHUS HF (NO) | 2022-04-07 | — | — | WO | claimed |
| CN-122094689-A | Combination therapy of diacylglycerol kinase (DGK) alpha inhibitors with other therapies | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122056886-A | Application of proflavine and derivative thereof in preparation of METTL B inhibitor | 深圳市人民医院 | 2026-05-19 | — | — | CN | disclosed |
| EP-4739310-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) INHIBITOR COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-05-13 | — | — | EP | disclosed |
| EP-4221706-B1 | TREATMENT FOR VIRAL INFECTION | UNIV OSLO HF (NO) | 2026-04-15 | — | — | EP | disclosed |
| US-20260024617-A1 | METHODS AND SYSTEMS FOR PERSONALIZED THERAPIES | SCIPHER MEDICINE CORP (US) | 2026-01-22 | — | — | US | disclosed |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240009213-A1 | TREATMENT FOR VIRAL INFECTION | LTK, LCK, EIF2AK2 | ALK 428/4885INSR 3146/4885IGF1R 2273/4885 |
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | PHKA1, PIK3CA, PHKA2 | ALK 370/4885INSR 751/4885IGF1R 477/4885 |
| US-20260024617-A1 | METHODS AND SYSTEMS FOR PERSONALIZED THERAPIES | SET, SSB, CNKSR1 | ALK 4335/4885INSR 1770/4885IGF1R 2145/4885 |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | ALK 316/4885INSR 767/4885IGF1R 543/4885 |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | ALK 316/4885INSR 767/4885IGF1R 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.